Pre-clinical and Clinical Studies of Cobinamide, a New Cyanide Detoxifying Agent

描述（由申请人提供）：氰化物是一种剧毒化合物，在科学实验室和工业环境中很容易获得。此外，它相对容易由廉价且可广泛获得的试剂合成。因此，氰化物有可能落入恐怖分子手中，并被用作大规模杀伤性武器。当氰化物在机场或火车站等封闭空间以气体形式释放时，尤其致命。美国只有两种氰化物解毒剂——硫代硫酸钠，以及亚硝酸钠和亚硝酸戊酯形式的亚硝酸盐。这两种药物都有显着的副作用和严重的局限性，包括它们在治疗大量因大量氰化物暴露而失去知觉的人时是不切实际的，因为硫代硫酸钠和亚硝酸钠必须静脉注射，而亚硝酸戊酯必须吸入几分钟。 Cobinamide 是钴胺素（维生素 B12）生物合成中的倒数第二个化合物，以极高的亲和力 (~1022 M-1) 结合两个氰化物分子。我们已经证明，cobinamide 是一种对小鼠、培养的哺乳动物细胞和果蝇非常有效的氰化物解毒剂。通过肌内注射可宾酰胺，可以从两倍于 LD50 的氰化物剂量中拯救小鼠，这使得可宾酰胺成为治疗大规模伤亡的有吸引力的药物。我们现在建议对可滨酰胺进行必要的临床前研究，以获得美国食品和药物管理局 (FDA) 的研究人员新药 (IND) 批准。临床前研究将在前三年内完成，在第四年和第五年期间，我们建议进行 I 期和 IIa 期临床研究。 II期研究将针对接受硝普钠治疗的急性高血压患者进行；由于硝普钠治疗受到氰化物毒性的限制，可宾酰胺可以允许硝普钠的给药时间更长、剂量更高。 Cobinamide 将成为针对氰化物暴露的药物疗法的一个受欢迎的补充；除了反击恐怖袭击和减少硝普钠毒性外，钴酰胺还可用于治疗烟雾吸入受害者、职业和工业氰化物暴露、吸烟者和血液透析患者。

DESCRIPTION (provided by applicant): Cyanide is a highly toxic compound that is readily available in scientific laboratories and industrial settings. Moreover, it is relatively easy to synthesize from inexpensive, widely obtainable reagents. Thus, cyanide has the potential to come into the hands of terrorists, and to be used as a weapon of mass destruction. Cyanide would be particularly lethal when released as a gas in closed spaces such as airports or train stations. Only two cyanide antidotes are available in the United States -- sodium thiosulfate, and nitrites in the form of sodium nitrite and amyl nitrite. Both agents have significant side effects and serious limitations, including they would be impractical in treating a large number of unconscious persons from mass cyanide exposure, because sodium thiosulfate and sodium nitrite must be administered intravenously, and amyl nitrite must be inhaled for several minutes. Cobinamide, the penultimate compound in the biosynthesis of cobalamin (vitamin B12), binds two cyanide molecules with extremely high affinity (~1022 M-1). We have shown that cobinamide is a remarkably effective cyanide antidote in mice, cultured mammalian cells, and Drosophila melanogaster. Mice can be rescued from a cyanide dose of two times the LD50 with an intramuscular injection of cobinamide, making cobinamide an attractive agent for treating mass casualties. We now propose to perform the requisite pre-clinical studies of cobinamide to obtain Investigator's New Drug (IND) approval from the Food and Drug Administration (FDA). The pre-clinical studies will be completed during the first three grant years, and during grant years four and five, we propose to perform Phase I and lla clinical studies. The Phase II studies will be performed on acutely hypertensive patients treated with nitroprusside; cobinamide could allow nitroprusside to be given for longer periods and at higher doses because nitroprusside therapy is limited by cyanide toxicity. Cobinamide would be a welcome addition to drug therapies directed against cyanide exposure; in addition to countering a terrorist attack and reducing nitroprusside toxicity, cobinamide could be used to treat smoke inhalation victims, occupational and industrial cyanide exposures, cigarette smokers, and hemodialysis patients.